PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
-
- STATUS
- Recruiting
-
- days left to enroll
- 72
-
- participants needed
- 40
-
- sponsor
- University Health Network, Toronto
Summary
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Description
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.
Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.
Details
| Condition | Complicated Grief, Chronic Renal Anemia, Renal Anemia, Joint Injuries, Catheter Complications, Spinocerebellar Disorders, Surviving Abuse, Primary Insulin Hypersecretion, Cancer Treatment, Indikation: Diabetes - Typ II, Myopic Macular Degeneration, Late Infantile Neuronal Ceroid Lipfuscinsosis, Effects of Chemotherapy, Dental Filling, Functional Dyspepsia, Anemic Cancer, Partial Medial Meniscectomy, Severe Premenstrual Symptom, Abdominal Surgery, Gambling Problems, Pulmonary Hypertension, Cancer Prevention, Pseudobulbar Affect, Nerve Injury, Testotoxikose, Recurrent Pregnancy Loss, Infantile Fibrosarcoma, Memory Problems, Stasis Dermatitis, Serial Evaluation of Ductal Epithelium, Open Heart Surgery, Chronic Pelvic Pain, Low Testosterone, Pulmonary Arterial Hypertension, Habit Reversal, Pelvic Adhesions, Mental Disability, Spine Athroplasty |
|---|---|
| Treatment | PET/MR with 18F-FDG |
| Clinical Study Identifier | NCT04901884 |
| Sponsor | University Health Network, Toronto |
| Last Modified on | 8 October 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer